In Brief: Neopath's Autopap
This article was originally published in The Gray Sheet
Executive Summary
Neopath's Autopap: Pap smear analysis product as a primary screening device will be reviewed by FDA's Hematology and Pathology Devices Panel on Jan. 28, the company reports. The PMA supplement would allow use of the Autopap to identify certain slides as not requiring a manual evaluation. Following the advisory panel's initial rejection of the supplement in September 1996, Neopath amended the application in August with prospective data from about 31,500 slides. The data show the system to be statistically "superior" to current practice in identifying a range of atypical Pap smears, according to the company. The Autopap currently is approved as a quality control rescreener of slides identified by technicians as negative...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.